Practical Considerations for the Diagnosis and Treatment of Fibrotic Interstitial Lung Disease During the Coronavirus Disease 2019 Pandemic.


Journal

Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 04 2020
revised: 15 04 2020
accepted: 17 04 2020
pubmed: 26 4 2020
medline: 18 9 2020
entrez: 26 4 2020
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2, has affected virtually all aspects of patient care. Health-care systems around the world are trying simultaneously to treat patients with COVID-19, prepare for its long-term impacts, and treat patients with other acute and chronic diseases. There are multiple ways that the COVID-19 pandemic will directly affect patients with fibrotic interstitial lung disease (ILD), particularly given their common risk factors for poor outcomes. Major issues for patients with ILD will include restricted access to key components of the diagnostic process, new uncertainties in the use of common ILD pharmacotherapies, limited ability to monitor both disease severity and the presence of medication adverse effects, and significantly curtailed research activities. The purpose of this review is to summarize how COVID-19 has impacted key components of the diagnosis and management of fibrotic ILD as well as to provide strategies to mitigate these challenges. We further review major obstacles for researchers and identify priority areas for future ILD research related to COVID-19. Our goals are to provide practical considerations to support the care of patients with ILD during the COVID-19 pandemic and to provide a road map for clinicians caring for these patients during future infectious disease outbreaks.

Identifiants

pubmed: 32333929
pii: S0012-3692(20)30756-X
doi: 10.1016/j.chest.2020.04.019
pmc: PMC7194738
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1069-1078

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Références

Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
N Engl J Med. 2014 May 29;370(22):2083-92
pubmed: 24836312
Am J Respir Crit Care Med. 2018 Mar 15;197(6):700-701
pubmed: 29227752
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Med (Lausanne). 2017 Oct 23;4:176
pubmed: 29109947
Lancet. 2020 Feb 22;395(10224):e35-e36
pubmed: 32035018
Respir Med. 2019 Jul;153:44-51
pubmed: 31153107
N Engl J Med. 2014 May 29;370(22):2071-82
pubmed: 24836310
Respir Res. 2019 May 24;20(1):103
pubmed: 31126287
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Am J Respir Crit Care Med. 2020 May 15;201(10):1299-1300
pubmed: 32228035
Eur Respir J. 2019 Feb 21;53(2):
pubmed: 30487208
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
N Engl J Med. 2003 Jul 31;349(5):507-8
pubmed: 12890854
Lung. 2016 Oct;194(5):739-43
pubmed: 27377558
Respir Med. 2019 Jan;146:42-48
pubmed: 30665517
Respirology. 2018 Apr;23(4):392-398
pubmed: 29193512
Lancet Infect Dis. 2020 Apr;20(4):411-412
pubmed: 32105638
Am J Respir Crit Care Med. 2017 Nov 15;196(10):1249-1254
pubmed: 28414524
Chest. 2008 May;133(5):1113-9
pubmed: 17989156
Eur Respir J. 2012 Jan;39(1):125-32
pubmed: 21737559
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
Infect Dis Clin North Am. 2019 Dec;33(4):869-889
pubmed: 31668196
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
J Thromb Haemost. 2020 May;18(5):1023-1026
pubmed: 32338827
Lancet Respir Med. 2020 Feb;8(2):147-157
pubmed: 31578169
Eur J Radiol. 2020 May;126:108961
pubmed: 32229322
N Engl J Med. 2019 Jun 27;380(26):2518-2528
pubmed: 31112379
Eur Respir J. 2020 Jun 4;55(6):
pubmed: 32265310
Lancet. 2011 May 21;377(9779):1760-9
pubmed: 21571362
Ann Am Thorac Soc. 2019 Jul;16(7):927-930
pubmed: 30950636
Am J Respir Crit Care Med. 2011 Oct 1;184(7):842-7
pubmed: 21719755
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68
pubmed: 30168753
Curr Opin Infect Dis. 2012 Aug;25(4):423-30
pubmed: 22766648
Eur Respir J. 2016 Nov;48(5):1453-1461
pubmed: 27660509
JAMA. 2020 May 12;323(18):1769-1770
pubmed: 32208485
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Am J Physiol Lung Cell Mol Physiol. 2008 Jul;295(1):L178-85
pubmed: 18441099
Am J Respir Crit Care Med. 2017 Jan 1;195(1):78-85
pubmed: 27331880
Drug Dev Res. 2020 Aug;81(5):537-540
pubmed: 32129518
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Eur Respir J. 2020 Apr 3;55(4):
pubmed: 32060068
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
N Engl J Med. 2019 Oct 31;381(18):1718-1727
pubmed: 31566307
Clin Exp Rheumatol. 2020 Mar-Apr;38(2):337-342
pubmed: 32202240
Chest. 2020 Jul;158(1):106-116
pubmed: 32275978

Auteurs

Alyson W Wong (AW)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada.

Lee Fidler (L)

Sunnybrook Health Sciences Centre, Department of Medicine, University of Toronto, Toronto, ON, Canada.

Veronica Marcoux (V)

Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada.

Kerri A Johannson (KA)

Department of Medicine, University of Calgary, Calgary, AB, Canada.

Deborah Assayag (D)

Department of Medicine, McGill University, Montreal, QC, Canada.

Jolene H Fisher (JH)

Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.

Nathan Hambly (N)

Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Martin Kolb (M)

Department of Medicine, Firestone Institute for Respiratory Health, McMaster University, Hamilton, ON, Canada.

Julie Morisset (J)

Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.

Shane Shapera (S)

Department of Medicine, University Health Network, University of Toronto, Toronto, ON, Canada.

Christopher J Ryerson (CJ)

Department of Medicine, University of British Columbia, Vancouver, BC, Canada; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, BC, Canada. Electronic address: chris.ryerson@hli.ubc.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH